|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Those with C282Y mutations had significantly more hepatic fibrosis than those without (p<0.05).
|
10488699 |
1999 |
|
rs1800471
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The objective of the present study was to elucidate possible relationships between four polymorphisms of the TGF-beta1 gene (-800G>A; -509C>T; Leu10Pro; Arg25Pro) and stage, histological activity grade and progression rate of liver fibrosis, classified according to the METAVIR-score.
|
11750277 |
2002 |
|
rs1800730
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The HFE S65C mutation may lead to mild to moderate hepatic iron overload but neither clinically manifest haemochromatosis nor iron associated extensive liver fibrosis was encountered in any of the patients carrying this mutation.
|
12377814 |
2002 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients carrying C282Y had higher mean hepatic iron concentrations (P=0.02), hepatic iron indices (P<=0.0001), and hepatic fibrosis scores (P=0.01).
|
12445428 |
2002 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs1799945
|
|
|
0.020 |
GeneticVariation |
BEFREE |
C282Y or H63D heterozygosity is an independent risk factor for liver fibrosis and cirrhosis in HCV infected individuals.
|
12586300 |
2003 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages.
|
12957298 |
2003 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
For C282Y heterozygous patients, the odds ratios for marked inflammatory activity (A2-4) and advanced liver fibrosis or cirrhosis (F2-4) are 4.9 and 4.6, respectively, compared with patients carrying homozygous wild-type alleles.
|
15287851 |
2004 |
|
rs1217691063
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, a genetic background such as the MTHFR C677T polymorphism responsible for hyperhomocysteinemia plays a role in the development of higher degree of steatosis, which in turn accelerates the progression of liver fibrosis in CHC.
|
15834927 |
2005 |
|
rs1430059719
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, adenoviral application of the mutants MMP-9-H401A and -E402Q led to increased apoptosis of activated hepatic stellate cells, thought to be the main promoters of hepatic fibrosis.
|
16507762 |
2006 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, glucose intolerance may be important risk factor for the development of hepatic fibrosis in subjects with the C282Y/H63D HFE genotype.
|
16584391 |
2006 |
|
rs1799945
|
|
|
0.020 |
GeneticVariation |
BEFREE |
However, glucose intolerance may be important risk factor for the development of hepatic fibrosis in subjects with the C282Y/H63D HFE genotype.
|
16584391 |
2006 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A minimum of .66% C282Y homozygotes have liver fibrosis.
|
16797244 |
2006 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis.
|
17680648 |
2007 |
|
rs1217691063
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion.
|
17900242 |
2008 |
|
rs7080536
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The G534E variant of FSAP is a risk locus for HCV-induced liver fibrosis and cirrhosis by determining PDGF-BB-mediated hepatic stellate cell proliferation through a single amino acid substitution in FSAP.
|
19105210 |
2009 |
|
rs267607117
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When examining a worldwide cohort of 62 independent patients with NPHP and associated liver fibrosis we identified altogether four novel mutations (p.W290L, p.C615R, p.G821S, and p.G821R) in five of them.
|
19508969 |
2009 |
|
rs9402373
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show that the single nucleotide polymorphism (SNP) rs9402373 that lies close to CTGF is associated with severe HF (P = 2 x 10(-6); odds ratio [OR] = 2.01; confidence interval of OR [CI] = 1.51-2.7) in two Chinese samples, in Sudanese, and in Brazilians infected with either Schistosoma japonicum or S. mansoni.
|
19822645 |
2009 |
|
rs267606959
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
A novel POLG gene mutation in 4 children with Alpers-like hepatocerebral syndromes.
|
20142534 |
2010 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.
|
20373368 |
2010 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6-8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1-21.0; <0.001), serum HCV-RNA less than 600,000 IU/ml (11.9; 3.8-37.4; <0.001) and lack of advanced liver fibrosis (3.5; 1.4-8.9; 0.009).
|
20389235 |
2010 |
|
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recently, the rs738409 C>G adiponutrin/patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism, which encodes the I148M protein variant in the catalytic domain, has been associated with severe steatosis, NASH, and liver fibrosis in adults.
|
20648474 |
2010 |
|
rs267606959
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Predicting the contribution of novel POLG mutations to human disease through analysis in yeast model.
|
20883824 |
2011 |
|
rs8099917
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Multivariate analysis (odds ratio; 95% confidence interval; P value) indicated that the rs8099917 TT genotype was a strong predictor of treatment success (5.83; 1.26-26.92; P = 0.021), independent of baseline plasma HCV-RNA load less than 500 000 IU/ml (4.85; 1.18-19.95; P = 0.025) and absence of advanced liver fibrosis (5.24; 1.20-22.91; P = 0.025).
|
21048934 |
2010 |
|
rs12075
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We here tested the hypothesis that this genetic variant (rs12075 A/G) is a risk factor for liver fibrosis in HCV infection.
|
21156192 |
2011 |